Cobra Biomanufacturing Completes cGMP Production Of Scancell’s SCIB1 DNA Vaccine

Cobra Biomanufacturing reported that the current Good Manufacturing Practice (cGMP) production of Scancell’s SCIB1 DNA vaccine has been successfully completed ahead of the planned clinical trials that are expected to commence on schedule in H1 2010.

SCIB1 is being developed for the treatment of melanoma, using Scancell’s patent-protected ImmunoBody technology platform that overcomes the current limitations of most cancer vaccines by generating the high-avidity T-cells that kill cancer cells.

The company said that the final release of the product for SCIB1 clinical trials is anticipated in mid-Q4 2009 and will be undertaken by Cobra’s in-house QP.

David Evans, chairman of Scancell, said: “Cobra Biomanufacturing has done an excellent job manufacturing our SCIB1 DNA vaccine on time and on budget. This is another important step forward towards our goal of starting clinical trials with SCIB1 in the first half of 2010.”

Simon Saxby, chief executive of Cobra Biomanufacturing, said: “It has been a pleasure to work with Scancell on the production of their SCIB1 vaccine. The two teams have worked closely together to make this a successful project and we wish Scancell every success with their clinical trials. The Cobra team look forward to working with Scancell in the future.”